抗血小板治疗与接受抗病毒治疗的慢性乙型肝炎患者肝细胞癌风险
该回顾性分析纳入1674例抗病毒治疗后HBV DNA<2000 IU/mL的慢性乙型肝炎患者,比较抗血小板组(558例)与非抗血小板组(1116例)。抗血小板治疗与肝细胞癌风险降低相关(HR 0.44,95%CI 0.23-0.85,P=0.01),但总体出血风险升高(HR 3.28,95%CI 1.98-5.42,P<0.001),尤其含氯吡格雷方案;单用阿司匹林未增加出血风险(HR 1.11,95%CI 0.48-2.54,P=0.81)。
要点
- 抗血小板治疗与慢性乙肝抗病毒治疗且HBV DNA<2000 IU/mL患者的肝细胞癌风险降低相关(HR 0.44)。
- 倾向评分匹配后抗血小板治疗仍与肝细胞癌风险降低相关(HR 0.34,95%CI 0.15-0.77)。
- 含氯吡格雷的抗血小板治疗与总体出血风险升高相关(HR 3.28),单用阿司匹林未增加出血风险。
核心结论
- 抗血小板治疗可降低病毒有效抑制的慢性乙型肝炎患者的肝细胞癌风险,但含氯吡格雷的抗血小板治疗可能增加出血风险。
研究设计与样本
- 回顾性分析,纳入2002年1月至2015年5月期间1674例经抗病毒治疗后血清HBV DNA<2000 IU/mL的慢性乙型肝炎患者。
- 抗血小板组558例(阿司匹林、氯吡格雷或两者联用),非抗血小板组1116例。
- 主要结局为肝细胞癌发生,次要结局为出血事件,采用时变Cox比例风险模型和倾向评分匹配分析。
主要发现
- 研究期间63例(3.8%)发生肝细胞癌。
- 时变Cox分析中,抗血小板组肝细胞癌风险显著低于非抗血小板组(HR 0.44,95%CI 0.23-0.85,P=0.01),与抗血小板药物种类无关。
- 倾向评分匹配后,抗血小板治疗显著降低肝细胞癌风险(HR 0.34,95%CI 0.15-0.77,P=0.01)。
- 抗血小板组总体出血风险高于非抗血小板组(HR 3.28,95%CI 1.98-5.42,P<0.001),尤其含氯吡格雷方案。
- 单用阿司匹林与出血风险升高无关(HR 1.11,95%CI 0.48-2.54,P=0.81)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Antiplatelet therapy has shown protective effects against hepatocellular carcinoma (HCC) in preclinical studies. However, it is unclear whether antiplatelet therapy lowers the risk of HCC in patients with chronic hepatitis B. A retrospective analysis was conducted of data from 1,674 chronic hepatitis B patients, enrolled between January 2002 and May 2015, whose serum hepatitis B virus DNA levels were suppressed by antivirals to <2,000 IU/mL. The primary and secondary outcomes were development of HCC and bleeding events, respectively. Risk was compared between patients with antiplatelet treatment (aspirin, clopidogrel, or both; antiplatelet group) and patients who were not treated (non-antiplatelet group) using a time-varying Cox proportional hazards model for total population and propensity score-matching analysis. The antiplatelet group included 558 patients, and the non-antiplatelet group had 1,116 patients. During the study period, 63 patients (3.8%) developed HCC. In time-varying Cox proportional analyses, the antiplatelet group showed a significantly lower risk of HCC (hazard ratio [HR], 0.44; 95% confidence interval [CI], 0.23-0.85; P = 0.01), regardless of antiplatelet agent. In propensity score-matched pairs, antiplatelet therapy significantly reduced the risk of HCC (HR, 0.34; 95% CI, 0.15-0.77; P = 0.01). However, the overall risk of bleeding was higher in the antiplatelet group (HR, 3.28; 95% CI, 1.98-5.42; P < 0.001), particularly for clopidogrel with or without aspirin. Treatment with aspirin alone was not associated with a higher bleeding risk (HR, 1.11; 95% CI, 0.48-2.54; P = 0.81). CONCLUSION: Antiplatelet therapy reduces the risk of HCC in chronic hepatitis B patients whose hepatitis B virus is effectively suppressed. However, antiplatelet therapy containing clopidogrel may increase the risk of bleeding. (Hepatology 2017;66:1556-1569).
引用
- Lee M, Chung GE, Lee JH, et al. Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment. Hepatology. 2017. PMID: 28617992. doi:10.1002/hep.29318
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。